Foscarnet: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Foscarnet" ([Edit=Allow only autoconfirmed users] (expires 15:57, 14 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:57, 14 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{drugbox
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
| IUPAC_name = phosphonomethanoic acid
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Foscarnet|{{fontcolor|#6C7B8B|Foscarnet}}]]'''''
| image = Fascarnet.png|100px
|-
| CAS_number = 63585-09-1
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | OSCAVIR<sup>®</sup> FDA Package Insert
| ATC_prefix = J05
|-
| ATC_suffix = AD01
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet description|Description]]
| PubChem = 3415
|-
| DrugBank = APRD00669
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet clinical pharmacology|Clinical Pharmacology]]
| C = 1 |H = 3 |O = 5 |P = 1
|-
| molecular_weight = 126.005 [[Gram|g]]/[[Mole (unit)|mol]]<br>300.1 g/mol <small>(foscarnet trisodium hexahydrate)</small>
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet microbiology|Microbiology]]
| bioavailability = NA
|-
| protein_bound = 14-17%
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet indications and usage|Indications and Usage]]
| metabolism =
|-
| elimination_half-life = 3.3-6.8 hours
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet contraindications|Contraindications]]
| pregnancy_category = B3 <small>([[Australia|Au]])</small>, C <small>([[United States|U.S.]])</small>
|-
| legal_status = ℞-only <small>(U.S.)</small>, [[Prescription drug|POM]] <small>([[United Kingdom|UK]])</small>
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet warnings and precautions|Warnings and Precautions]]
| routes_of_administration = [[Intravenous therapy|Intravenous]]
|-
}}
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet adverse reactions|Adverse Reactions]]
'''Foscarnet''' is the [[conjugate base]] of the [[chemical compound]] with the [[chemical formula|formula]] HO<sub>2</sub>CPO<sub>3</sub>H<sub>2</sub>.  This [[phosphonic acid]] derivative is (marketed by [[AstraZeneca]] as foscarnet [[sodium]] under the trade name Foscavir&reg;) is an [[antiviral]] [[medication]] used to treat [[herpes viruses]], including [[cytomegalovirus]] (CMV) and [[herpes simplex]] viruses types 1 and 2 (HSV-1 and HSV-2).  It is particularly used to treat [[CMV retinitis]].
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet drug interactions|Drug Interactions]]
==Mechanism of action==
|-
Foscarnet is a structural mimic of the anion [[pyrophosphate]] that selectively inhibits the pyrophosphate binding site on viral [[DNA polymerase]]s at [[concentration]]s that do not affect human DNA polymerases.  Because foscarnet is not activated by [[thymidine kinase]], it maintains activity in some viruses which have lost thymidine kinase activity to gain resistance to [[aciclovir]] or [[ganciclovir]].  Therefore, foscarnet is often used in aciclovir- or ganciclovir-resistant disease.  However, acyclovir or ganciclovir resistant mutants with alterations in viral DNA polymerase may be resistant to foscarnet.
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet overdosage|Overdosage]]
 
|-
==Administration==
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet clinical studies|Clinical Studies]]
[[Intravenous]] only
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet dosage and administration|Dosage and Administration]]
==Side effects==
|-
*[[Renal failure]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet how supplied|How Supplied]]
*[[hypocalcaemia|Decreased calcium levels]]
|-
 
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Foscarnet labels and packages|Labels and Packages]]
{{Antivirals}}
|-
 
|}
[[Category:Antivirals]]
 
{{antimicrobial-stub}}
 
[[de:Foscarnet]]
[[es:Foscarnet]]
[[fr:Foscarnet]]
[[nl:Foscarnet]]

Revision as of 00:23, 5 January 2014

Foscarnet
OSCAVIR® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages
Retrieved from "https://www.wikidoc.org/index.php?title=Foscarnet&oldid=924160"